JP2013532971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532971A5 JP2013532971A5 JP2013515914A JP2013515914A JP2013532971A5 JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5 JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- homodimeric protein
- protein according
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004169 proteins and genes Human genes 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 3
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006500 Brucellosis Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35851310P | 2010-06-25 | 2010-06-25 | |
| EP10167291.3 | 2010-06-25 | ||
| EP10167291 | 2010-06-25 | ||
| US61/358,513 | 2010-06-25 | ||
| PCT/EP2011/060628 WO2011161244A1 (en) | 2010-06-25 | 2011-06-24 | Homodimeric protein constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016154365A Division JP6538622B2 (ja) | 2010-06-25 | 2016-08-05 | ホモ二量体タンパク質コンストラクト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532971A JP2013532971A (ja) | 2013-08-22 |
| JP2013532971A5 true JP2013532971A5 (enExample) | 2014-08-14 |
Family
ID=42983487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515914A Withdrawn JP2013532971A (ja) | 2010-06-25 | 2011-06-24 | ホモ二量体タンパク質コンストラクト |
| JP2016154365A Active JP6538622B2 (ja) | 2010-06-25 | 2016-08-05 | ホモ二量体タンパク質コンストラクト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016154365A Active JP6538622B2 (ja) | 2010-06-25 | 2016-08-05 | ホモ二量体タンパク質コンストラクト |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10590195B2 (enExample) |
| EP (2) | EP2585107B1 (enExample) |
| JP (2) | JP2013532971A (enExample) |
| KR (2) | KR102044948B1 (enExample) |
| CN (1) | CN102985109B (enExample) |
| AU (1) | AU2011268934B2 (enExample) |
| CA (1) | CA2803058C (enExample) |
| DK (1) | DK2585107T3 (enExample) |
| RU (1) | RU2624041C2 (enExample) |
| WO (1) | WO2011161244A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004215489B2 (en) * | 2003-02-25 | 2010-07-15 | Nykode Therapeutics ASA | Modified antibody |
| WO2011161244A1 (en) * | 2010-06-25 | 2011-12-29 | Vaccibody As | Homodimeric protein constructs |
| EP3533462A1 (en) | 2011-12-21 | 2019-09-04 | Vaccibody AS | Vaccines against hpv |
| JP2019505512A (ja) * | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| KR102682118B1 (ko) * | 2016-04-29 | 2024-07-08 | 주식회사유한양행 | Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도 |
| EP3515951B1 (en) | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
| AU2021253641B2 (en) * | 2020-04-07 | 2026-08-06 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| US20230165952A1 (en) * | 2020-05-01 | 2023-06-01 | Nykode Therapeutics ASA | Betacoronavirus prophylaxis and therapy |
| WO2022013277A1 (en) * | 2020-07-14 | 2022-01-20 | Evaxion Biotech A/S | Apc targeting units for immunotherapy |
| AU2022244191A1 (en) | 2021-03-26 | 2023-09-28 | Nykode Therapeutics ASA | Therapeutic combination for treating cancer |
| WO2022233851A1 (en) | 2021-05-03 | 2022-11-10 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| IL308310A (en) | 2021-05-10 | 2024-01-01 | Nykode Therapeutics ASA | Co-expression of immune-stimulating structures and compounds |
| WO2022238432A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Co-expression of constructs and immunoinhibitory compounds |
| EP4337247A1 (en) | 2021-05-10 | 2024-03-20 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
| WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| KR20240007235A (ko) | 2021-05-10 | 2024-01-16 | 니코데 테라퓨틱스 에이에스에이 | 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도 |
| EP4426344A1 (en) | 2021-11-03 | 2024-09-11 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| US20260193669A1 (en) | 2022-11-09 | 2026-07-09 | Nykode Therapeutics ASA | Co-Expression of Constructs and Polypeptides |
| KR20260074976A (ko) | 2023-09-19 | 2026-05-27 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 펩티드 및 이의 용도 |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| CN122438694A (zh) | 2023-12-19 | 2026-07-21 | 瑞泽恩制药公司 | Foxp3肽及其用途 |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5646016A (en) | 1991-02-06 | 1997-07-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules |
| US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| AU5361794A (en) | 1992-10-14 | 1994-05-09 | Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
| WO1998006863A1 (en) | 1996-08-14 | 1998-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A vector for polynucleotide vaccines |
| GB9820014D0 (en) | 1998-09-14 | 1998-11-04 | Cancer Res Campaign Tech | Receptor antagonists and uses thereof |
| US20030125521A1 (en) | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| DE60216287T2 (de) | 2001-07-13 | 2007-05-31 | Nanocarrier Co., Ltd. | Lyophilisierende zusammensetzung von wirkstoff-verkapselnder polymer-mizelle und verfahren zu ihrer herstellung |
| US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
| ES2283759T3 (es) | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | Anticuerpos anti-igf-ir y sus aplicaciones. |
| JP2005527490A (ja) | 2002-01-18 | 2005-09-15 | イノヴィオ アーエス | 筋肉内投与のための二重特異性抗体ｄｎａ構築物 |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| AU2004215489B2 (en) | 2003-02-25 | 2010-07-15 | Nykode Therapeutics ASA | Modified antibody |
| ES2345200T3 (es) * | 2003-03-24 | 2010-09-17 | The Scripps Research Institute | Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas. |
| WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
| SI2447283T1 (sl) * | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc. | Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1) |
| US20090010948A1 (en) * | 2006-12-15 | 2009-01-08 | The University Of Hong Kong | Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10 |
| JP4954293B2 (ja) * | 2006-12-29 | 2012-06-13 | オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド | 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用 |
| CA2739608A1 (en) | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| WO2011161244A1 (en) | 2010-06-25 | 2011-12-29 | Vaccibody As | Homodimeric protein constructs |
| EP3053592B1 (en) | 2013-10-01 | 2025-04-23 | Mie University | T cell-inducing vaccine containing interepitope sequence promoting antigen presentation |
| EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
-
2011
- 2011-06-24 WO PCT/EP2011/060628 patent/WO2011161244A1/en not_active Ceased
- 2011-06-24 EP EP11727190.8A patent/EP2585107B1/en active Active
- 2011-06-24 CN CN201180031589.6A patent/CN102985109B/zh active Active
- 2011-06-24 DK DK11727190.8T patent/DK2585107T3/en active
- 2011-06-24 US US13/805,709 patent/US10590195B2/en active Active
- 2011-06-24 KR KR1020187024633A patent/KR102044948B1/ko active Active
- 2011-06-24 RU RU2013103335A patent/RU2624041C2/ru active
- 2011-06-24 JP JP2013515914A patent/JP2013532971A/ja not_active Withdrawn
- 2011-06-24 CA CA2803058A patent/CA2803058C/en active Active
- 2011-06-24 KR KR1020137002177A patent/KR20130087517A/ko not_active Ceased
- 2011-06-24 EP EP18195357.1A patent/EP3441085A1/en not_active Withdrawn
- 2011-06-24 AU AU2011268934A patent/AU2011268934B2/en active Active
-
2016
- 2016-08-05 JP JP2016154365A patent/JP6538622B2/ja active Active
-
2020
- 2020-02-07 US US16/784,778 patent/US11479605B2/en active Active
-
2022
- 2022-09-22 US US17/934,348 patent/US12516116B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| RU2013103335A (ru) | Конструкции гомодимерных белков | |
| Serradell et al. | Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins | |
| Raghuwanshi et al. | Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | |
| Zhang et al. | Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances | |
| JP5984388B2 (ja) | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン | |
| Fan et al. | Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes | |
| JP2017507117A5 (enExample) | ||
| ES2775278T3 (es) | Composición formada por un antígeno ligado a un ligando de la superfamilia TNF | |
| JP2015508284A5 (enExample) | ||
| JP2008541768A5 (enExample) | ||
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| Gupta et al. | A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | |
| JP2015509707A5 (enExample) | ||
| JP2012509071A5 (enExample) | ||
| JP2016516723A5 (enExample) | ||
| KR20160105452A (ko) | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 | |
| CN104039833A (zh) | 针对hpv的疫苗 | |
| US20250099575A1 (en) | Mrna vaccine | |
| CA2831294A1 (en) | Compositions and methods to immunize against hepatitis c virus | |
| CN105143251B (zh) | 流感核蛋白疫苗 | |
| JP2023518340A5 (enExample) | ||
| JP2021515588A5 (enExample) | ||
| Kawai et al. | Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses |